Coherus BioSciences (CHRS) Misses Q2 EPS by 60c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.02 +2.00%
EPS Growth %: +39.4%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
FNLC, LSBK, OVLY, More
EPS Growth %: +39.4%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
FNLC, LSBK, OVLY, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($1.71), $0.60 worse than the analyst estimate of ($1.11). Revenue for the quarter came in at $844 thousand, versus $10.2 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pharming Group N.V. (PHAR) Reports Q3 results; offers guidance
- Rollins falls 7% on third quarter earnings and revenue miss
- First Bancorp (FNLC) Tops Q3 EPS by 95c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
